1. Correlation Between the VerifyNow P2Y
- Author
-
Kodai, Uematsu, Tasuku, Sakayori, Hidekazu, Ishida, Yukari, Omori, Keisuke, Kitano, Hirofumi, Matsubara, and Yukiko, Enomoto
- Subjects
Adult ,Aged, 80 and over ,Blood Platelets ,Male ,Platelet Aggregation ,Platelet Function Tests ,Middle Aged ,Clopidogrel ,Adenosine Diphosphate ,Humans ,Female ,Blood Coagulation Tests ,Platelet Aggregation Inhibitors ,Aged - Abstract
Light transmission aggregometry (LTA) is the gold standard method for assessing platelet function. Recently, a new parameter called adenosine diphosphate (ADP)-induced platelet aggregation level (APAL) was developed to aid interpretation of LTA results. APAL is a score calculated based on platelet aggregation patterns upon exposure to 1 μM and 10 μM ADP and is determined using an automated coagulation analyzer. We compared APAL and VerifyNow P2Y42 patients who have received antiplatelet therapy were studied. Platelet function tests were performed on CS-2400 for APAL and VerifyNow P2YModerate correlations were observed between APAL and PRU (r=0.64,The APAL system exhibits moderate correlation with PRU and % inhibition. APAL testing is a good choice for a clinical laboratory already in possession of Sysmex CS series analyzers. In this setting, APAL testing can significantly decrease the cost of platelet function testing for patients on antiplatelet therapy.
- Published
- 2020